These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30547371)

  • 41. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preclinical models of non-alcoholic fatty liver disease.
    Santhekadur PK; Kumar DP; Sanyal AJ
    J Hepatol; 2018 Feb; 68(2):230-237. PubMed ID: 29128391
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.
    Chuah KH; Wan Yusoff WNI; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK
    Liver Int; 2019 Jul; 39(7):1315-1324. PubMed ID: 30825254
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
    Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
    Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [NASH (non-alcoholic steatohepatitis): fatty liver or fatal liver disease?].
    Roeb E
    Zentralbl Chir; 2014 Apr; 139(2):168-74. PubMed ID: 22441997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-alcoholic fatty liver disease: a survey of involvement of primary care physicians.
    Mari A; Omari S; Abu Baker F; Abu Much S; Said Ahmad H; Khoury T; Nseir W; Mahamid M
    Minerva Gastroenterol Dietol; 2019 Dec; 65(4):255-258. PubMed ID: 31646850
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment.
    Aggio D; Gallop K; Wittrup-Jensen V; Farsani SF; Lloyd AJ
    J Comp Eff Res; 2024 Feb; 13(2):e230033. PubMed ID: 38226909
    [No Abstract]   [Full Text] [Related]  

  • 49. Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients.
    Danford CJ; Iriana S; Shen C; Curry MP; Lai M
    Liver Int; 2019 Jun; 39(6):1165-1173. PubMed ID: 30809932
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels.
    Zheng KI; Liu WY; Pan XY; Ma HL; Zhu PW; Wu XX; Targher G; Byrne C; Wang XD; Chen YP; Lu F; Zheng MH
    BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32139603
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ultrasound Fatty Liver Indicator: A Simple Tool for Differentiating Steatosis From Nonalcoholic Steatohepatitis: Validity in the Average Obese Population.
    Nelson SM; Hoskins JD; Lisanti C; Chaudhuri J
    J Ultrasound Med; 2020 Apr; 39(4):749-759. PubMed ID: 31647137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of cough and mucus on COPD patients: primary insights from an exploratory study with an Online Patient Community.
    Cook N; Gey J; Oezel B; Mackay AJ; Kumari C; Kaur VP; Larkin N; Harte J; Vergara-Muro S; Gutzwiller FS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1365-1376. PubMed ID: 31417250
    [No Abstract]   [Full Text] [Related]  

  • 55. Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis.
    Federico A; Dallio M; Caprio GG; Gravina AG; Picascia D; Masarone M; Persico M; Loguercio C
    Nutrients; 2017 Sep; 9(10):. PubMed ID: 28956816
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.
    Carlsson B; Lindén D; Brolén G; Liljeblad M; Bjursell M; Romeo S; Loomba R
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1305-1320. PubMed ID: 32383295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
    Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
    Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis.
    Ogawa K; Kobayashi T; Furukawa JI; Hanamatsu H; Nakamura A; Suzuki K; Kawagishi N; Ohara M; Umemura M; Nakai M; Sho T; Suda G; Morikawa K; Baba M; Furuya K; Terashita K; Kobayashi T; Onodera M; Horimoto T; Shinada K; Tsunematsu S; Tsunematsu I; Meguro T; Mitsuhashi T; Hato M; Higashino K; Shinohara Y; Sakamoto N
    Sci Rep; 2020 Jan; 10(1):321. PubMed ID: 31941930
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Visual Liver Score to Stratify Non-Alcoholic Steatohepatitis Risk and Determine Selective Intraoperative Liver Biopsy in Obesity.
    Ooi GJ; Burton PR; Earnest A; Laurie C; Kemp WW; Nottle PD; McLean CA; Roberts SK; Brown WA
    Obes Surg; 2018 Feb; 28(2):427-436. PubMed ID: 28776153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.